Photodynamic Therapy for Central Early-Stage Lung Cancer: A Retrospective Comparative Study of Photofrin, Chlorin e6, and Foscan
Respiration · 2026
DOI: 10.1159/000550182 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Respiration, 2026. Verfasst von Tom Sondermann und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Interventional Pneumology, Department of Pulmonary Medicine, University Hospital Essen - Ruhrlandklinik, Essen, Germany. Hauptthemen laut MEDLINE: Photochemotherapy, Lung Neoplasms, Photosensitizing Agents, Dihematoporphyrin Ether. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben.
Abstract (Originalsprache)
Introduction
Photodynamic therapy (PDT) is a minimally invasive, organ-preserving treatment option for patients with centrally located early-stage non-small cell lung cancer. While first-generation photosensitizers such as Photofrin are well established, second-generation agents like Chlorin e6 offer improved pharmacokinetics and potentially better clinical outcomes. The objective of this study was to assess the safety profile and therapeutic efficacy of different photosensitizers used in PDT for centrally located early-stage lung cancer (CELC).
Methods
We retrospectively analyzed 62 CELC lesions in 36 patients treated with PDT between 2015 and 2024. Patients received one of three photosensitizers – Photofrin, Chlorin e6, or Foscan – followed by bronchoscopic light activation. Outcomes included complete remission (CR), local tumor control (LTC), disease-free survival (DFS), and treatment-related adverse events.
Results
CR rates were 87.5% (28/32) for Chlorin e6, 100% (3/3) for Foscan, and 68.8% (22/32) for Photofrin, with a nonsignificant trend favoring Chlorin e6 over Photofrin (p = 0.13). Mean DFS was longest in the Chlorin e6 group (43.3 months; 95% CI: 32.5–54.1), followed by Photofrin (24.0 months; 95% CI: 17.2–30.8) and Foscan (7.3 months; 95% CI: 6.3–8.4). Durable LTC was achieved in 84.1% of lesions without need for escalation to systemic or surgical treatment. Chlorin e6 demonstrated a more favorable safety profile than Photofrin.
Conclusion
PDT is a safe and effective treatment modality for CELC, achieving high rates of LTC. Among the evaluated photosensitizers, Chlorin e6 showed a favorable balance of efficacy and safety.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Interventional Pneumology, Department of Pulmonary Medicine, University Hospital Essen - Ruhrlandklinik, Essen, Germany.
- Department of Pulmonary Medicine, Lungenklinik Hemer, Hemer, Germany.
- Synverdis GmbH, Heidelberg, Germany.
- Institute of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, Essen, Germany.
- Department of Pulmonary Medicine, University Hospital Essen - Ruhrlandklinik, Essen, Germany.
- Division of Interventional Pneumology, Department of Pulmonary Medicine, University Hospital Essen - Ruhrlandklinik, Essen, Germany, erik.buescher@rlk.uk-essen.de.
Zitieren
APA
Sondermann, T., Darwiche, K., Freitag, L., Hüttenberger, D. F., Wienker, J., Opitz, M., Taube, C., & Büscher, E. (2026). Photodynamic Therapy for Central Early-Stage Lung Cancer: A Retrospective Comparative Study of Photofrin, Chlorin e6, and Foscan. Respiration. https://doi.org/10.1159/000550182
Vancouver
Sondermann T, Darwiche K, Freitag L, Hüttenberger DF, Wienker J, Opitz M, et al. Photodynamic Therapy for Central Early-Stage Lung Cancer: A Retrospective Comparative Study of Photofrin, Chlorin e6, and Foscan. Respiration. 2026. doi:10.1159/000550182
BibTeX
@article{Sondermann2026,
author = {Sondermann, Tom and Darwiche, Kaid and Freitag, Lutz and Hüttenberger, Dirk Friedrich and Wienker, Johannes and Opitz, Marcel and Taube, Christian and Büscher, Erik},
title = {Photodynamic Therapy for Central Early-Stage Lung Cancer: A Retrospective Comparative Study of Photofrin, Chlorin e6, and Foscan},
journal = {Respiration},
year = {2026},
doi = {10.1159/000550182}
}
EUVIMED